Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.
The pharmacokinetic profile of UK-49,858 (fluconazole), a novel triazole antifungal agent which is being developed for oral and intravenous use, was determined in mice, rats, dogs, and humans. Comparative data following oral and intravenous administration showed that bioavailability was essentially complete in all four species. Peak concentrations in plasma of drug normalized to a 1-mg/kg dose level following oral administration, were relatively high: 0.7, 0.6, 1.1, and 1.4 micrograms/ml in mice, rats, dogs, and humans, respectively. The volumes of distribution ranged between 1.1 liter/kg in mice and 0.7 liter/kg in humans, which are approximate to the values for total body water. Whole body autoradiography studies in mice following intravenous administration of [14C]UK-49,858 demonstrated that the drug was evenly distributed throughout the tissues, including the central nervous system and the gastrointestinal tract. Plasma protein binding was low (11 to 12%) in all species. Marked species differences were observed in elimination half-lives, with mean values of 4.8, 4.0, 14, and 22 h in mice, rats, dogs, and humans, respectively. The major route of elimination of the drug was renal clearance, with about 70% of the dose being excreted unchanged in the urine in each species. Studies with [14C]UK-49,858 on metabolism and excretion (intravenous and oral) in mice and dogs showed that about 90% of the dose was recovered as unchanged drug in urine and feces, confirming the metabolic stability of the drug. This pharmacokinetic profile is markedly different from that of imidazole antifungal drugs and undoubtedly contributes to the excellent efficacy of UK-49,858 in vivo.
D000293:Adolescent; D000328:Adult; D000818:Animals; D000935:Antifungal Agents / Q000378:metabolism*; D001345:Autoradiography; D001682:Biological Availability; D001798:Blood Proteins / Q000378:metabolism; D004285:Dogs; D005260:Female; D015725:Fluconazole; D006801:Humans; D007700:Kinetics; D008297:Male; D051379:Mice; D008875:Middle Aged; D011485:Protein Binding; D051381:Rats; D013045:Species Specificity; D014018:Tissue Distribution; D014230:Triazoles / Q000378:metabolism*
D000935:Antifungal Agents; D001798:Blood Proteins; D014230:Triazoles; D015725:Fluconazole